Rexafor 20mg Injection

About

Rexafor 20mg Injection contains Plerixafor, a CXCR4 chemokine receptor antagonist. This medication is used in combination with granulocyte-colony stimulating factor (G-CSF) to mobilize hematopoietic stem cells (HSCs) to the peripheral blood for collection and subsequent autologous transplantation. It is indicated for patients with non-Hodgkin lymphoma (NHL) and multiple myeloma (MM). Plerixafor works by blocking the binding of stromal cell-derived factor-1 alpha (SDF-1α) to the CXCR4 receptor on hematopoietic stem cells. This disruption of the SDF-1α/CXCR4 axis dislodges HSCs from the bone marrow microenvironment, facilitating their release into the bloodstream where they can be collected via apheresis.

This mechanism significantly improves the efficiency of stem cell mobilization, particularly in patients who are poor mobilizers with G-CSF alone, thereby increasing the likelihood of successful autologous stem cell transplantation.

Uses

• Mobilization of HSCs for autologous transplant in NHL
• Mobilization of HSCs for autologous transplant in MM
• Patients who are poor mobilizers with G-CSF alone
• Enhancing stem cell collection efficiency

Directions For Use

Administered as a subcutaneous injection by a healthcare professional. Typically given daily for up to 4 days prior to apheresis.

Benefits

• Improves stem cell mobilization and collection.
• Increases the likelihood of successful autologous transplant.
• Reduces the number of apheresis sessions needed.
• Effective in patients who failed prior mobilization.
• Well-tolerated with a predictable safety profile.
• Crucial for patients undergoing high-dose chemotherapy.

Side Effects

• Diarrhea
• Nausea
• Fatigue
• Injection site reactions
• Abdominal pain
• Headache
• Dizziness
• Vomiting
• Arthralgia
• Peripheral edema
• Increased white blood cell count
• Splenomegaly (rare)

Safety Measures

• Alcohol - No specific contraindication, but avoid excessive alcohol to prevent dehydration or exacerbate gastrointestinal side effects.
• Pregnancy - Contraindicated. Plerixafor can cause fetal harm. Use effective contraception during treatment and for 1 week after the last dose.
• Breastfeeding - Contraindicated. It is unknown if plerixafor is excreted in human milk; advise women not to breastfeed during treatment.
• Liver - Use with caution in patients with severe hepatic impairment. No specific dose adjustment for mild-moderate, but severe impairment data is limited.
• Kidney - Use with caution in patients with moderate to severe renal impairment. Dose adjustments are necessary based on creatinine clearance.
• Lung - Monitor for any new or worsening respiratory symptoms, though direct lung toxicity is not a primary concern.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.